Microbot Medical Inc. (MBOT): Price and Financial Metrics
MBOT Price/Volume Stats
| Current price | $1.40 | 52-week high | $5.87 |
| Prev. close | $1.64 | 52-week low | $1.00 |
| Day low | $1.38 | Volume | 531,300 |
| Day high | $1.82 | Avg. volume | 1,427,597 |
| 50-day MA | $2.21 | Dividend yield | N/A |
| 200-day MA | $2.56 | Market Cap | 16.39M |
MBOT Stock Price Chart Interactive Chart >
Microbot Medical Inc. (MBOT) Company Bio
Microbot Medical Inc. operates as a medical device company. The Company specializes in the research, design, development, and commercialization of micro-robotics assisted medical technologies. Microbot Medical offers its services in the United States.
Latest MBOT News From Around the Web
Below are the latest news stories about MICROBOT MEDICAL INC that investors may wish to consider to help them evaluate MBOT as an investment opportunity.
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023The presentation follows successful extensive uses of the Company’s endovascular robotic system in pre-clinical studiesBRAINTREE, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is honored to announce the continuous growing global recognition of its LIBERTY® Robotic Surgical System, to be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The abstract is to be present |
Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical SystemThe Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercializationBRAINTREE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces another step in its commitment to advance the commercialization processes of LIBERTY® with th |
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory BoardProfessor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announces the expansion of its global team of experts supporting the Company as scientific advisory board members ("SAB"), with Francois H. Cornelis, MD, PhD j |
Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in EuropeEngagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European UnionHINGHAM, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced the first steps towards its planned European market clearance, by engaging with a leading Notified Body. The Notified Body will audit the Company to |
MBOT Price Returns
| 1-mo | -32.04% |
| 3-mo | -59.18% |
| 6-mo | -39.39% |
| 1-year | -75.48% |
| 3-year | -81.46% |
| 5-year | -79.97% |
| YTD | -53.49% |
| 2022 | -59.87% |
| 2021 | 8.85% |
| 2020 | -32.25% |
| 2019 | 491.28% |
| 2018 | -88.76% |
Loading social stream, please wait...